ADMA Biologics Inc (ADMA) reported disappointing financial results for the third quarter of fiscal 2025. The company recorded earnings per share (EPS) of $0.15, matching Wall Street's expectations but failing to exceed them. Revenue also came in at $0.1 billion, aligning with analyst forecasts yet indicating no growth.
This update provides insight into ADMA's operational performance amidst potential challenges in the biotechnology sector, where the company operates as a biopharmaceutical entity focused on manufacturing and marketing specialty plasma-derived biologics. Headquartered in Ramsey, New Jersey, ADMA Biologics produces three FDA-approved products aimed at treating immune deficiencies and preventing infectious diseases: ASCENIV, BIVIGAM, and NABI-HB.
The firm employs 677 full-time staff and has a market capitalisation of $3,339.11 million, with a trailing P/E ratio of 15.98 and a TTM EPS of 0.85. Investors may wish to review the full earnings release and participate in the earnings conference call scheduled for later today to gain further context on the company's performance and future outlook.
Looking ahead, ADMA is expected to report EPS of 0.2142 and revenue of $0.2 billion on August 3, 2026, as well as EPS of 0.2006 and revenue of $0.1 billion on May 4, 2026.